Nurosene Enters Into Agreement With Taylored Biotherapeutics to Evaluate Clinical Trial Results

TORONTO, June 22, 2022 /CNW/ – Nurosene Health Inc. (“Nurosene” or the “Company”) (CSE: MEND) (Frankfurt: 8TV) (OTC: MNNDF), a healthtech company focused on delivering innovative AI-based technology solutions for mental performance and wellness, enters into a Master Service Agreement with Taylored Biotherapeutics (“Taylored”), an early-stage biotechnology company focused on developing safe and effective microbial based therapies, or ‘psychobiotics’, to treat mental illness.

As part of the MSA, a fixed fee-based Scope of Work (SOW) has been agreed to, whereby Taylored will utilize Nurosene’s NetraAI technology to evaluate clinical trial results.

“The exciting work that is happening at Taylored Biotherapeutics approaches mental health via the gut microbiome, which generates complex data sets for heterogeneous patient populations. This makes our NetraAI the perfect platform to support their AI pipeline as they advance through their clinical trials. We are looking forward to partnering with the team from Taylored to advance their efforts,” said Dr. Joseph Geraci, Chief Scientific Officer.